Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Opthea Spon American Depositary Receipts Representing 8 Ord Shs OPT

Alternate Symbol(s):  CKDXF

Healthcare Biotechnology
Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two... see more

Recent & Breaking News (NDAQ:OPT)

Opthea Appoints Chief Commercial Officer to Lead Commercialization of OPT-302 for Wet AMD

GlobeNewswire January 3, 2022

Opthea Granted Chinese Patent Covering OPT-302

GlobeNewswire October 26, 2021

Opthea Opens Patient Enrollment in the Asia-Pacific Region for the OPT-302 ShORe and COAST Phase 3 Trials in Wet AMD

GlobeNewswire October 19, 2021

Opthea Opens Patient Recruitment in Europe for Pivotal Phase 3 ShORe and COAST Wet AMD Trials of OPT-302

GlobeNewswire October 4, 2021

Opthea To Present at September Investor Conferences

GlobeNewswire September 2, 2021

Opthea Reports Fiscal Year 2021 Financial Results and Corporate Highlights

GlobeNewswire August 30, 2021

Opthea's Phase 1 Data From Wet AMD Clinical Trial Presented at EURETINA Congress 2016

Marketwired September 12, 2016

Opthea to Host Conference Call Providing Update on Phase 1 Wet AMD Clinical Trial With OPT-302

Marketwired July 25, 2016

Opthea Doses First Patient in Phase 2A Dose Expansion Study for OPT-302 in Wet AMD

Marketwired May 5, 2016

Opthea Phase 1 Wet AMD Clinical Trial With OPT-302 Meets Primary Safety Objective

Marketwired April 21, 2016

Opthea Completes Patient Enrolment for OPT-302 Phase 1 Dose Escalation Trial in Patients With Wet AMD

Marketwired March 30, 2016

Opthea Signs Cell Line Development Commercial License Agreement with Selexis SA for Wet AMD Product

PR Newswire January 13, 2014

DSM and Opthea Sign Agreement to Manufacture Opthea's Lead Product for Eye Disease

PR Newswire October 29, 2013

VEGF-C Shown to Have Major Role in Age-Related Macular Degeneration (AMD)

Globe Newswire May 8, 2013